The December issue of the Journal of the Neurological Sciences Vol 479
Issue highlights
Research Article
Critical nodes in precision diagnosis and treatment of Alzheimer's disease: exploration of multidimensional biomarkers and prospects for targeted interventionZuo et al.Published online: October 28, 2025
Alzheimer' s disease (AD), characterized by cognitive decline and progressive neurodegeneration, remains a major clinical and scientific challenge due to its complex pathophysiology and marked heterogeneity. Important signs of the disease, like the buildup of β-amyloid, changes in Tau proteins, inflammation in the brain, and problems with mitochondria, form the basis for developing targeted treatments. This review summarizes recent advances in the identification of therapeutic targets and multi-dimensional biomarkers, such as liquid, imaging, and multi-omics-based markers. These biomarkers hold potential for early diagnosis, disease subtyping, and therapeutic response monitoring. We suggest that combining biomarkers and treatment targets could be a key approach to improving personalized care for AD. |
|
Research Article
Factors influencing timeliness of reporting results from multiple sclerosis related clinical trials to ClinicalTrials.govCwajna et al.Published online: November 3, 2025Published online: October 28, 2025
Timely reporting of clinical trial results is both an ethical obligation and a legal requirement under Section 801 of the Food and Drug Administration Amendments Act (FDAAA). The law mandates that results from applicable clinical trials be submitted to ClinicalTrials.gov within 12 months of the study's primary completion date. We examined reporting compliance among multiple sclerosis (MS)-related randomized controlled trials registered on ClinicalTrials.gov. |
|
Research Article | Open Access
Association between benzodiazepines and dementia: A case-control study from Canadian health surveys and medico-administrative databasesLegrand et al.Published online: November 2, 2025
This study's objective was to examine whether BZD exposure, duration and elimination half-life are independently associated with incident dementia, and explore confounding by the prodromal period.
|
|
Research Article
Enhanced diagnosis accuracy of tuberculous meningitis using mycolic and tuberculostearic acid via advanced mass spectrometrySingh et al.Published online: November 13, 2025
This was a tertiary hospital-based prospective study conducted on (n = 172) meningitis who were classified into the definite TBM, probable TBM, possible TBM, and non TBM groups, based on microbiological gold standards and the Marais scoring system. CSF parameters, including glucose, protein, white blood cell (WBC) count, and adenosine deaminase (ADA) levels, were measured. MA and TBSA biomarker levels were quantified by tandem mass spectrometry. Diagnostic performance was evaluated based on sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and the area under the receiver operating characteristic curve (AUC) by comparing between definite TBM and non TBM categories. |
Web design by Tribal Systems